|
1
|
Morrow JJ, Bayles I, Funnell APW, Miller
TE, Saiakhova A, Lizardo MM, Bartels CF, Kapteijn MY, Hung S,
Mendoza A, et al: Positively selected enhancer elements endow
osteosarcoma cells with metastatic competence. Nat Med. 24:176–185.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Isakoff MS, Bielack SS, Meltzer P and
Gorlick R: Osteosarcoma: Current treatment and a collaborative
pathway to success. J Clin Oncol. 33:3029–3035. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li S, Sun W, Wang H, Zuo D, Hua Y and Cai
Z: Research progress on the multidrug resistance mechanisms of
osteosarcoma chemotherapy and reversal. Tumour Biol. 36:1329–1338.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xu J, Wang H, Hu Y, Zhang YS, Wen L, Yin
F, Wang Z, Zhang Y, Li S, Miao Y, et al: Inhibition of CaMKIIα
activity enhances antitumor effect of fullerene C60 nanocrystals by
suppression of autophagic degradation. Adv Sci (Weinh).
6:18012332019. View Article : Google Scholar
|
|
6
|
Chen R, Wang G, Zheng Y, Hua Y and Cai Z:
Drug resistance-related microRNAs in osteosarcoma: Translating
basic evidence into therapeutic strategies. J Cell Mol Med.
23:2280–2292. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang Y, Duan G and Feng S: MicroRNA-301a
modulates doxorubicin resistance in osteosarcoma cells by targeting
AMP-activated protein kinase alpha 1. Biochem Biophys Res Commun.
459:367–373. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Luetke A, Meyers PA, Lewis I and Juergens
H: Osteosarcoma treatment - where do we stand? A state of the art
review. Cancer Treat Rev. 40:523–532. 2014. View Article : Google Scholar
|
|
9
|
Camuzard O, Santucci-Darmanin S, Carle GF
and Pierrefite-Carle V: Role of autophagy in osteosarcoma. J Bone
Oncol. 16:1002352019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kumar A, Singh UK and Chaudhary A:
Targeting autophagy to overcome drug resistance in cancer therapy.
Future Med Chem. 7:1535–1542. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
O'Farrill JS and Gordon N: Autophagy in
osteosarcoma. Adv Exp Med Biol. 804:147–160. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
D'Arcy MS: Cell death: A review of the
major forms of apoptosis, necrosis and autophagy. Cell Biol Int.
43:582–592. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nagelkerke A, Sweep FC, Geurts-Moespot A,
Bussink J and Span PN: Therapeutic targeting of autophagy in
cancer. Part I: Molecular pathways controlling autophagy. Semin
Cancer Biol. 31:89–98. 2015. View Article : Google Scholar
|
|
14
|
Klionsky DJ, Abdelmohsen K, Abe A, Abedin
MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD,
Adeli K, et al: Guidelines for the use and interpretation of assays
for monitoring autophagy (3rd edition). Autophagy. 12:1–222. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nagelkerke A, Bussink J, Geurts-Moespot A,
Sweep FC and Span PN: Therapeutic targeting of autophagy in cancer.
Part II: Pharmacological modulation of treatment-induced autophagy.
Semin Cancer Biol. 31:99–105. 2015. View Article : Google Scholar
|
|
16
|
Schott CR, Ludwig L, Mutsaers AJ, Foster
RA and Wood GA: The autophagy inhibitor spautin-1, either alone or
combined with doxorubicin, decreases cell survival and colony
formation in canine appendicular osteosarcoma cells. PLoS One.
13:e02064272018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
He H, Ni J and Huang J: Molecular
mechanisms of chemoresistance in osteosarcoma (Review). Oncol Lett.
7:1352–1362. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hollomon MG, Gordon N, Santiago-O'Farrill
JM and Kleinerman ES: Knockdown of autophagy-related protein 5,
ATG5, decreases oxidative stress and has an opposing effect on
camptothecin-induced cytotoxicity in osteosarcoma cells. BMC
Cancer. 13:5002013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhao Z, Tao L, Shen C, Liu B, Yang Z and
Tao H: Silencing of Barkor/ATG14 sensitizes osteosarcoma cells to
cisplatin induced apoptosis. Int J Mol Med. 33:271–276. 2014.
View Article : Google Scholar
|
|
20
|
Wu W, Li W, Zhou Y and Zhang C: Inhibition
of beclin1 affects the chemotherapeutic sensitivity of
osteosarcoma. Int J Clin Exp Pathol. 7:7114–7122. 2014.PubMed/NCBI
|
|
21
|
Shen C, Wang W, Tao L, Liu B, Yang Z and
Tao H: Chloroquine blocks the autophagic process in
cisplatin-resistant osteosarcoma cells by regulating the expression
of p62/SQSTM1. Int J Mol Med. 32:448–456. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xu ZM, Li CB, Liu QL, Li P and Yang H:
Ginsenoside Rg1 prevents doxorubicin-induced cardiotoxicity through
the inhibition of autophagy and endoplasmic reticulum stress in
mice. Int J Mol Sci. 19:192018. View Article : Google Scholar
|
|
23
|
Zhou P, Li Y, Li B, Zhang M, Xu C, Liu F,
Bian L, Liu Y, Yao Y and Li D: Autophagy inhibition enhances
celecoxib-induced apoptosis in osteosarcoma. Cell Cycle.
17:997–1006. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Guo Y, Huang C, Li G, Chen T, Li J and
Huang Z: Paxilitaxel induces apoptosis accompanied by protective
autophagy in osteosarcoma cells through hypoxia-inducible factor-1α
pathway. Mol Med Rep. 12:3681–3687. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu K, Ren T, Huang Y, Sun K, Bao X, Wang
S, Zheng B and Guo W: Apatinib promotes autophagy and apoptosis
through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma. Cell Death
Dis. 8:e30152017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Huang J, Ni J, Liu K, Yu Y, Xie M, Kang R,
Vernon P, Cao L and Tang D: HMGB1 promotes drug resistance in
osteosarcoma. Cancer Res. 72:230–238. 2012. View Article : Google Scholar
|
|
27
|
Huang J, Liu K, Yu Y, Xie M, Kang R,
Vernon P, Cao L, Tang D and Ni J: Targeting HMGB1-mediated
autophagy as a novel therapeutic strategy for osteosarcoma.
Autophagy. 8:275–277. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pistoia V and Pezzolo A: Involvement of
HMGB1 in resistance to tumor vessel-targeted, monoclonal
antibody-based immunotherapy. J Immunol Res. 2016:31423652016.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kim M, Jung JY, Choi S, Lee H, Morales LD,
Koh JT, Kim SH, Choi YD, Choi C, Slaga TJ, et al: GFRA1 promotes
cisplatin-induced chemoresistance in osteosarcoma by inducing
autophagy. Autophagy. 13:149–168. 2017. View Article : Google Scholar :
|
|
30
|
Kim M and Kim DJ: GFRA1: A novel molecular
target for the prevention of osteosarcoma chemoresistance. Int J
Mol Sci. 19:192018.
|
|
31
|
Xu R, Liu S, Chen H and Lao L:
MicroRNA-30a downregulation contributes to chemoresistance of
osteosarcoma cells through activating Beclin-1-mediated autophagy.
Oncol Rep. 35:1757–1763. 2016. View Article : Google Scholar
|
|
32
|
Chen R, Li X, He B and Hu W: MicroRNA-410
regulates autophagy-related gene ATG16L1 expression and enhances
chemosensitivity via autophagy inhibition in osteosarcoma. Mol Med
Rep. 15:1326–1334. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wei R, Cao G, Deng Z, Su J and Cai L:
miR-140-5p attenuates chemotherapeutic drug-induced cell death by
regulating autophagy through inositol 1,4,5-trisphosphate kinase 2
(IP3k2) in human osteosarcoma cells. Biosci Rep. 36:362016.
View Article : Google Scholar
|
|
34
|
Meng Y, Gao R, Ma J, Zhao J, Xu E, Wang C
and Zhou X: MicroRNA-140-5p regulates osteosarcoma chemoresistance
by targeting HMGN5 and autophagy. Sci Rep. 7:4162017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chen L, Jiang K, Jiang H and Wei P:
miR-155 mediates drug resistance in osteosarcoma cells via inducing
autophagy. Exp Ther Med. 8:527–532. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang L, Tang B, Han H, Mao D, Chen J, Zeng
Y and Xiong M: miR-155 affects osteosarcoma MG-63 cell autophagy
induced by adriamycin through regulating PTEN-PI3K/AKT/mTOR
signaling pathway. Cancer Biother Radiopharm. 33:32–38. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Guo S, Bai R, Liu W, Zhao A, Zhao Z, Wang
Y, Wang Y, Zhao W and Wang W: miR-22 inhibits osteosarcoma cell
proliferation and migration by targeting HMGB1 and inhibiting
HMGB1-mediated autophagy. Tumour Biol. 35:7025–7034. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li X, Wang S, Chen Y, Liu G and Yang X:
miR-22 targets the 3′UTR of HMGB1 and inhibits the HMGB1-associated
autophagy in osteosarcoma cells during chemotherapy. Tumour Biol.
35:6021–6028. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang P, Zhao ZQ, Guo SB, Yang TY, Chang
ZQ, Li DH, Zhao W, Wang YX, Sun C, Wang Y, et al: Roles of
microRNA-22 in suppressing proliferation and promoting sensitivity
of osteo-sarcoma cells via metadherin-mediated autophagy. Orthop
Surg. 11:285–293. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chang Z, Huo L, Li K, Wu Y and Hu Z:
Blocked autophagy by miR-101 enhances osteosarcoma cell
chemosensitivity in vitro. ScientificWorldJournal. 2014:7947562014.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhou J, Wu S, Chen Y, Zhao J, Zhang K,
Wang J and Chen S: microRNA-143 is associated with the survival of
ALDH1+CD133+ osteosarcoma cells and the
chemoresistance of osteosarcoma. Exp Biol Med (Maywood).
240:867–875. 2015. View Article : Google Scholar
|
|
42
|
Li Y, Jiang W, Hu Y, Da Z, Zeng C, Tu M,
Deng Z and Xiao W: MicroRNA-199a-5p inhibits cisplatin-induced drug
resistance via inhibition of autophagy in osteosarcoma cells. Oncol
Lett. 12:4203–4208. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Liu K, Hou Y, Liu Y and Zheng J: LncRNA
SNHG15 contributes to proliferation, invasion and autophagy in
osteosarcoma cells by sponging miR-141. J Biomed Sci. 24:462017.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wang Z, Liu Z and Wu S: Long non-coding
RNA CTA sensitizes osteosarcoma cells to doxorubicin through
inhibition of autophagy. Oncotarget. 8:31465–31477. 2017.PubMed/NCBI
|
|
45
|
Yu Z, Li N, Jiang K, Zhang N and Yao LL:
MiR-100 up-regulation enhanced cell autophagy and apoptosis induced
by cisplatin in osteosarcoma by targeting mTOR. Eur Rev Med
Pharmacol Sci. 22:5867–5873. 2018.PubMed/NCBI
|
|
46
|
Wu G, Yu W, Zhang M, Yin R, Wu Y and Liu
Q: MicroRNA-145-3p suppresses proliferation and promotes apotosis
and autophagy of osteosarcoma cell by targeting HDAC4. Artif Cells
Nanomed Biotechnol. 46(Suppl 2): 579–586. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yang C, Gao R, Wang J, Yuan W, Wang C and
Zhou X: High-mobility group nucleosome-binding domain 5 increases
drug resistance in osteosarcoma through upregulating autophagy.
Tumour Biol. 35:6357–6363. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Shimizu T, Sugihara E, Yamaguchi-Iwai S,
Tamaki S, Koyama Y, Kamel W, Ueki A, Ishikawa T, Chiyoda T, Osuka
S, et al: IGF2 preserves osteosarcoma cell survival by creating an
autophagic state of dormancy that protects cells against
chemotherapeutic stress. Cancer Res. 74:6531–6541. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhen YF, Li ST, Zhu YR, Wang XD, Zhou XZ
and Zhu LQ: Identification of DNA-PKcs as a primary resistance
factor of salinomycin in osteosarcoma cells. Oncotarget.
7:79417–79427. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wang H, Li W, Xu J, Zhang T, Zuo D, Zhou
Z, Lin B, Wang G, Wang Z, Sun W, et al: NDRG1 inhibition sensitizes
osteosarcoma cells to combretastatin A-4 through targeting
autophagy. Cell Death Dis. 8:e30482017. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Xiao X, Wang W, Li Y, Yang D, Li X, Shen
C, Liu Y, Ke X, Guo S and Guo Z: HSP90AA1-mediated autophagy
promotes drug resistance in osteosarcoma. J Exp Clin Cancer Res.
37:2012018. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Tao H, Chen F, Liu H, Hu Y, Wang Y and Li
H: Wnt/β-catenin signaling pathway activation reverses gemcitabine
resistance by attenuating Beclin1-mediated autophagy in the MG63
human osteosarcoma cell line. Mol Med Rep. 16:1701–1706. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Mukherjee S, Dash S, Lohitesh K and
Chowdhury R: The dynamic role of autophagy and MAPK signaling in
determining cell fate under cisplatin stress in osteosarcoma cells.
PLoS One. 12:e01792032017. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Zhang Y, Chen P, Hong H, Wang L, Zhou Y
and Lang Y: JNK pathway mediates curcumin-induced apoptosis and
autophagy in osteosarcoma MG63 cells. Exp Ther Med. 14:593–599.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Guan J, Yuan Z, He J, Wu Z, Liu B, Lin X,
Mo L and Mo H: Overexpression of caveolin-1 reduces Taxol
resistance in human osteosarcoma cells by attenuating PI3K-Akt-JNK
dependent autophagy. Exp Ther Med. 12:2815–2822. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Ouyang L, Shi Z, Zhao S, Wang FT, Zhou TT,
Liu B and Bao JK: Programmed cell death pathways in cancer: A
review of apoptosis, autophagy and programmed necrosis. Cell
Prolif. 45:487–498. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Li J, Yang Z, Li Y, Xia J, Li D, Li H, Ren
M, Liao Y, Yu S, Chen Y, et al: Cell apoptosis, autophagy and
necroptosis in osteosarcoma treatment. Oncotarget. 7:44763–44778.
2016.PubMed/NCBI
|
|
58
|
Zhao S, Lu N, Chai Y and Yu X: Rapamycin
inhibits tumor growth of human osteosarcomas. J BUON. 20:588–594.
2015.PubMed/NCBI
|
|
59
|
Zhao GS, Gao ZR, Zhang Q, Tang XF, Lv YF,
Zhang ZS, Zhang Y, Tan QL, Peng DB, Jiang DM, et al: TSSC3 promotes
autophagy via inactivating the Src-mediated PI3K/Akt/mTOR pathway
to suppress tumorigenesis and metastasis in osteosarcoma, and
predicts a favorable prognosis. J Exp Clin Cancer Res. 37:1882018.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Huang JC, Cui ZF, Chen SM, Yang LJ, Lian
HK, Liu B, Su ZH, Liu JS, Wang M, Hu ZB, et al: NVP-BEZ235
synergizes cisplatin sensitivity in osteosarcoma. Oncotarget.
9:10483–10496. 2017.
|
|
61
|
Meschini S, Condello M, Marra M, Formisano
G, Federici E and Arancia G: Autophagy-mediated chemosensitizing
effect of the plant alkaloid voacamine on multidrug resistant
cells. Toxicol In Vitro. 21:197–203. 2007. View Article : Google Scholar
|
|
62
|
Huang K, Chen Y, Zhang R, Wu Y, Ma Y, Fang
X and Shen S: Honokiol induces apoptosis and autophagy via the
ROS/ERK1/2 signaling pathway in human osteosarcoma cells in vitro
and in vivo. Cell Death Dis. 9:1572018. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Yen JH, Huang ST, Huang HS, Fong YC, Wu
YY, Chiang JH and Su YC: HGK-sestrin 2 signaling-mediated autophagy
contributes to antitumor efficacy of Tanshinone IIA in human
osteosarcoma cells. Cell Death Dis. 9:10032018. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Kang Y, He P, Wang H, Ye Y, Li X, Xie P
and Wu B: Brazilin induces FOXO3A-dependent autophagic cell death
by disturbing calcium homeostasis in osteosarcoma cells. Cancer
Chemother Pharmacol. 82:479–491. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Liu Y, Zhang Y, Zou J, Yan L, Yu X, Lu P,
Wu X, Li Q, Gu R and Zhu D: Andrographolide induces autophagic cell
death and inhibits invasion and metastasis of human osteosarcoma
cells in an autophagy-dependent manner. Cell Physiol Biochem.
44:1396–1410. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Zhang Y, Ma R, Cheng S and Gu G:
Marrubenol inhibits osteosarcoma cancer cell growth by inducing
autophagic cell death and inhibiting cancer cell migration and
invasion. J BUON. 23:729–734. 2018.PubMed/NCBI
|
|
67
|
Liu ZR, Sun LZ, Jia TH and Jia DF:
β-Aescin shows potent antiproliferative activity in osteosarcoma
cells by inducing autophagy, ROS generation and mitochondrial
membrane potential loss. J BUON. 22:1582–1586. 2017.
|
|
68
|
Zhu J, Yu W, Liu B, Wang Y, Shao J, Wang
J, Xia K, Liang C, Fang W, Zhou C, et al: Escin induces
caspase-dependent apoptosis and autophagy through the ROS/p38 MAPK
signalling pathway in human osteosarcoma cells in vitro and in
vivo. Cell Death Dis. 8:e31132017. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Yang D, Zhang H, Wu J, Ma R, Li Z, Wang K
and Yang F: The role of chamaejasmine in cellular apoptosis and
autophagy in MG-63 cells. Biosci Rep. 39:392019. View Article : Google Scholar
|
|
70
|
Zhang C and Wang LM: Inhibition of
autophagy attenuated curcumol-induced apoptosis in MG-63 human
osteosarcoma cells via Janus kinase signaling pathway. Oncol Lett.
14:6387–6394. 2017.PubMed/NCBI
|
|
71
|
Liao YX, Zhou CH, Zeng H, Zuo DQ, Wang ZY,
Yin F, Hua YQ and Cai ZD: The role of the CXCL12-CXCR4/CXCR7 axis
in the progression and metastasis of bone sarcomas (Review). Int J
Mol Med. 32:1239–1246. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Bao X, Zhao L, Guan H and Li F: Inhibition
of LCMR1 and ATG12 by demethylation-activated miR-570-3p is
involved in the anti-metastasis effects of metformin on human
osteosarcoma. Cell Death Dis. 9:6112018. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Zhang F, Yan T, Guo W, Sun K, Wang S, Bao
X, Liu K, Zheng B, Zhang H and Ren T: Novel oncogene COPS3
interacts with Beclin1 and Raf-1 to regulate metastasis of
osteosarcoma through autophagy. J Exp Clin Cancer Res. 37:1352018.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Wang D, Bao F, Teng Y, Li Q and Li J:
MicroRNA-506-3p initiates mesenchymal-to-epithelial transition and
suppresses autophagy in osteosarcoma cells by directly targeting
SPHK1. Biosci Biotechnol Biochem. 83:836–844. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Liao YX, Fu ZZ, Zhou CH, Shan LC, Wang ZY,
Yin F, Zheng LP, Hua YQ and Cai ZD: AMD3100 reduces CXCR4-mediated
survival and metastasis of osteosarcoma by inhibiting JNK and Akt,
but not p38 or Erk1/2, pathways in in vitro and mouse experiments.
Oncol Rep. 34:33–42. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Yu F, Li J, Xie Y, Sleightholm RL and
Oupicky D: Polymeric chloroquine as an inhibitor of cancer cell
migration and experimental lung metastasis. J Control Release.
244:347–356. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Yu W, Wang Y, Zhu J, Jin L, Liu B, Xia K,
Wang J, Gao J, Liang C and Tao H: Autophagy inhibitor enhance
ZnPc/BSA nanoparticle induced photodynamic therapy by suppressing
PD-L1 expression in osteosarcoma immunotherapy. Biomaterials.
192:128–139. 2019. View Article : Google Scholar
|
|
78
|
Ren T, Zheng B, Huang Y, Wang S, Bao X,
Liu K and Guo W: Osteosarcoma cell intrinsic PD-L2 signals promote
invasion and metastasis via the RhoA-ROCK-LIMK2 and autophagy
pathways. Cell Death Dis. 10:2612019. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Livingston JA, Wang WL, Tsai JW, Lazar AJ,
Leung CH, Lin H, Advani S, Daw N, Santiago-O'Farrill J, Hollomon M,
et al: Analysis of HSP27 and the autophagy marker LC3B+
puncta following preoperative chemotherapy identifies high-risk
osteo-sarcoma patients. Mol Cancer Ther. 17:1315–1323. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Lu Y, Wang Q, Zhou Y, Sun L, Hu B, Xue H,
Li M, Zhang K, Ren C, Duan N, et al: Overexpression of p62 is
associated with poor prognosis and aggressive phenotypes in
osteosarcoma. Oncol Lett. 15:9889–9895. 2018.PubMed/NCBI
|
|
81
|
Ma H, Li X, Wang J, Hornicek FJ, Garbutt
CC, Chang X and Duan Z: Expression and clinical implication of
autophagy-associated protein p62 in osteosarcoma. Oncology.
95:52–60. 2018. View Article : Google Scholar : PubMed/NCBI
|
